$ASPE

Aspen Neuroscience, Inc.

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.

No enriched coverage for $ASPE in the last 7 days.

$35.0M
—
ARCH Venture Fund X, L.P.
0%
See all $ASPE insider activity →
Low

ARCH Venture Partners X Discloses 12.9% Stake in Aspen Neuroscience

ARCH Venture Partners X and affiliated funds disclosed a 12.9% stake in Aspen Neuroscience, equal to 3.75 million shares. They acquired 1.33 million shares at $15 each during the IPO on Nov. 2, 2026. The group stated its investment is for long-term purposes with no immediate plans to alter the company's business or control.

OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake

OrbiMed Advisors disclosed a 12.3% stake in Aspen Neuroscience, acquired through preferred-stock conversions and IPO shares at $15 each. The investment is for financial purposes, not control, according to the firm's Nov. 6, 2026, Schedule 13D filing. OrbiMed is a registered investment adviser managing the fund holding the shares.

ASPE sentiment & insider activity

Recent ASPE coverage spans insider activity, financial news and corporate actions.

In the last 30 days, ASPE insiders filed 4 SEC Form 4 transactions — 4 purchases ($35.0M) and no sales. The most active reporter was ARCH Venture Fund X, L.P. with 2 filings.

What's driving ASPE

AlphAI scores every news story that mentions ASPE with an AI model for sentiment and relevance, and aggregates insider trades from Aspen Neuroscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ASPE

Score
$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

$ASPEHighAI 9/10Offering· $140.6M · closed

Aspen Neuroscience, Inc. (ASPE): Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year

Aspen Neuroscience, Inc. (ASPE) filed an SEC Form 8-K — Other Events. Item 5.03 Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year. On November 2, 2026, in connection with the closing of the initial public offering (the “ IPO ”) of Aspen Neuroscience, Inc. (the “ Company ”), the Company’s amended and restated certificate of

Related tickers